Spero announces GSK resubmission of NDA for tebipenem HBr to treat cUTI
Spero Therapeutics (NASDAQ:SPRO) announced today that its development partner, GSK (NYSE:GSK), has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, a treatment for complicated urinary tract infections (cUTI), including pyelonephritis.























